Prescription Drug Search

Strengths available for Baraclude:

Baraclude 0.5mg
Baraclude 1mg

Strengths available for Baraclude solution:

Baraclude solution 0.5mg/mL

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about CancerDrugsDirect.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Baraclude:

  • Algeria
  • Aruba
  • Azerbaijan
  • Bangladesh
  • Barbados
  • Belarus
  • Bolivia
  • Bosnia and Herzegovina
  • Chile
  • China
  • Cook Islands
  • Croatia
  • European Union
  • Fiji
  • Finland
  • France
  • Germany
  • Grenada
  • Hong Kong
  • India
  • Iraq
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Korea, South
  • Kuwait
  • Latvia
  • Liechtenstein
  • Nicaragua
  • Paraguay
  • Portugal
  • Qatar
  • Seychelles
  • Slovenia
  • Taiwan
  • Ukraine
  • United Kingdom, UK
  • United States, US
  • Vietnam
View All Countries

Latest news releases on Baraclude:

Generic floodgates open for Plavix in U.S. - FiercePharma

Plavix last year accounted for 33% of its revenue. They were encouraged by growing sales of some new drugs in the first quarter, including cancer drug Yervoy, hepatitis B drug Baraclude, and Sprycel, a drug for chronic myeloid leukemia ...

"World Hepatitis Treatment and Vaccine Market Will Reach $8.7bn in 2012" Visiongain Report Predicts - PR-USA.net

In 2011, only two blockbusters existed in the market - Baraclude for treating hepatitis B and Incivek for treating hepatitis C. Visiongain forecasts strong growth in revenue for both products early in the forecast period. However, patent expiries for ...

World Hepatitis Treatment and Vaccine Market will Reach $8.7Bn in 2012 Predicts Visiongain Report - Newswiretoday.com

In 2011, only two blockbusters existed in the market - Baraclude for treating hepatitis B and Incivek for treating hepatitis C. Visiongain forecasts strong growth in revenue for both products early in the forecast period. However, patent expiries for ...

Also in the press - onmedica.com

for arthritis (27,000 pounds), Bristol-Myers Squibb's Baraclude (entecavir) for hepatitis B (14,000 pounds per QALY) and Elan/Biogen Idec's Tysabri (natalizumab) for multiple sclerosis (35,000 pounds per QALY).

Customer Service
1-866-799-3435 (Use Discount Code 10782) | Contact Form
Copyright © 2012 CancerDrugsDirect.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK